Bb2121 CAR-T Multiple Myeloma Treatment Effective, but Benefits May Wane Bb2121 CAR-T Multiple Myeloma Treatment Effective, but Benefits May Wane

Doctors testing a chimeric antigen receptor T-cell (CAR-T) therapy against relapsed or refractory multiple myeloma say results from 33 patients show a complete response rate of 45%, although 40% of those patients with a complete response ultimately relapsed.Reuters Health Information
Source: Medscape Pathology Headlines - Category: Pathology Tags: Hematology-Oncology News Source Type: news